← Back to TCM Global · All articles
2026-10-23
The skincare launch is what the market saw. The 2025 annual report shows something larger: Giant Biogene is exploring ginsenoside applications across sleep health, anemia improvement, anti-fatigue and memory enhancement — positioning one core ingredient family across multiple consumer health categories.
Rare saponins have drawn research interest in sleep-related pathways; the category also has proven consumer demand (ginseng sleep products reported 86% efficacy in recent formula research). Status: early exploration.
Nutritional support for blood parameters is a traditional ginseng association now being studied with modern hematology markers. Status: exploratory.
The strongest evidence base of the four — including a Seoul RCT showing standardized ginseng extract cutting chronic-fatigue scores 34%, and fermented ginsenoside trials. Status: supported by external literature, internal products TBD.
Ginseng's neuroprotective research (including the BBB-crossing prodrug and Compound K work we've covered) provides mechanistic grounding. Status: mechanism-rich, product-early.
This is the platform-ingredient play: rather than one product with one claim, the company builds a portfolio where the same registered, mass-produced actives serve:
Each new application multiplies the value of the existing registration and production assets.
The reporting is appropriately careful: these applications are at varying research stages and do not equal regulatory-recognized efficacy or commercialized products. This is the correct discipline — research roadmaps are not claims.
A registered, mass-produced ingredient family plus a multi-category research map is exactly what a platform biotech looks like on paper. Execution — evidence by evidence, category by category — is now everything.
Explore more Eastern wellness wisdom at TCM Global.